search
Back to results

Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Primary Purpose

Epilepsy

Status
Terminated
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Zonegran
Sponsored by
Eisai GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epilepsy focused on measuring Epilepsy

Eligibility Criteria

18 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria at screening: Adult aged between 18 years and 74 years Focal epileptic seizures with or without secondary generalization Present treatment with one or two antiepileptic drugs (constant dosage during 8 weeks baseline phase prior to initiation of treatment with zonisamide). Stimulation of the vagus nerve is permitted and will not be counted as antiepileptic drug. For women of childbearing potential (postmenopausal for more than 1 year): possible pregnancy during the study can be excluded (by hysterectomy, sterilization or simultaneous application of two recognized methods of contraception (no oral contraceptives only) For male patients with partners of childbearing potential: a safe method of contraception is practiced during their study participation Written consent to participate in the study Inclusion criteria for randomisation: At least 6 focal or clonicotonic seizures documented completely in a seizure diary or the patient chart during the 8 prospective or retrospective weeks baseline phase. Exclusion criteria at screening: Epileptic state during the past year Non-epileptic fits Generalized epilepsy More than 4 weeks of seizure freedom during baseline phase Concomitant progressive CNS disease including progressive myoclonus epilepsy Concomitant treatment with vigabatrine and / or topiramate Hepatic and/or renal insufficiency (creatine > 2mg% or GPT > 2 times ULN) Body weight ≤ 40 kg (History of) kidney stones; erythrocyturia, family history (in parents, children, brothers and sisters or grandparents) of kidney stones (History of) drug and/or alcohol dependence Active psychosis Suicide attempt during the past 3 years Pre-treatment with zonisamide Known hypersensitivity to sulfonamides concomitant treatment with neuroleptic drugs pregnant or breast feeding woman participation in another therapy study within 3 months prior to or during this study blood donation planned during or within 4 weeks after the participation in this study elective surgery planned during the participation in this study patient is not willing or not capable to meet the study demands patient does not agree to the forwarding of his/her pseudonymous data patient without legal competence Exclusion criteria for randomisation: - More than 4 consecutive weeks of freedom from seizure during baseline phase

Sites / Locations

  • Epilepsieklinik Tabor
  • Universtitatsklinikum Bonn
  • Universtitatsklinikum Munster, Klinik und Poliklinik fur Neurologie
  • Epilepsiezentrum Bethel/KSE
  • Institut fur Diagnostik der Epilepsien Gmbh
  • Charite Campus Virchow-Klinikum, Neurologische Klinik und Poliklinik
  • St. Josephs Hospital, Neurologische Klinik
  • Dr. Gunther Schumann
  • Knappschaftskrankenhaus Bochum-Langendreer, Neurologische Klinik
  • Dr. Hans Martin Kolbinger
  • Neuro-Consil Gmbh
  • Neurologische Klinik der Universitat Erlangen
  • Universitatsklinik Essen, Klinik und Poliklinik fur Neurologie
  • Universitatsklinikum Freiburg, Neurozentrum
  • Universitatsklinikum Gottingen, Abt. fur klinische Neurophysiologie
  • Gemeinschaftpraxis fur Neurologie und Psychiatrie
  • Dr. Heinrich C. Braeuer
  • Ev. Krankenhaus Alsterdorf, Epilepsiezentrum Alsterdorf
  • Epilepsiezentrum Kork
  • Epilepsiezentrum Kleinwachau, Epilepsieambulanz
  • Universitatsklinikum Mannheim, Neurologische Klinik, Ambulanz fur Anfallserkrankte
  • Universitatsklinikum, Interdisziplinares Epilepsiezentrum
  • Klinikum Grosshadern, Neurologische Klinik und Poliklinik, Epilepsie-Ambulanz
  • Klinikum Offenbach, Neurologie
  • Klinik Ernst von Bergmann
  • Universitat Regensburg, Klinik un Poliklinik fur Neurologie
  • Klinik "Die Weissenau", Anfallsambulanz
  • Universitat Rostock, Klinik fur Neurologie und Poliklinik
  • Universitatsklinik Ulm Poliklinik fur Neurologie, Epilepsieambulanz
  • Dr. Horst-Schmidt Klinik, Neurologie

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

1

2

Arm Description

Outcomes

Primary Outcome Measures

Change in number of epileptic seizures between week 13 and 16 after start of treatment compared to the correspondently normalized base-line phase.

Secondary Outcome Measures

Full Information

First Posted
September 13, 2005
Last Updated
June 26, 2014
Sponsor
Eisai GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT00165828
Brief Title
Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
Official Title
Randomized Trial to Assess Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Terminated
Study Start Date
May 2005 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
February 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eisai GmbH

4. Oversight

5. Study Description

Brief Summary
Patients with focal epileptic seizures with or without generalization who are at present treated with one or two antiepileptic drugs are eligible for this study, provided that they fulfill all inclusion criteria and none of the exclusion criteria. Following a baseline phase of 8 weeks duration, the patients are randomised and they receive an initial daily dose of 50 mg zonisamide during the first week. The daily dose is then increased to 200 mg zonisamide in group A or 400 mg zonisamide in group B, respectively. After eight weeks of treatment, the daily dose in group A can be increased to 300 mg in case of insufficient efficacy. Control assessments are performed at the beginning of the study and at the end of the prospective baseline phase, if applicable and after 4, 8, 12, and 16 weeks. At the end of the first, second, and third treatment week, and at the end of week six, the patient is additionally contacted by telephone. Efficacy and safety parameters are assessed at baseline, during all control visits, and at the end of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
Epilepsy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
157 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Zonegran
Intervention Description
Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
Primary Outcome Measure Information:
Title
Change in number of epileptic seizures between week 13 and 16 after start of treatment compared to the correspondently normalized base-line phase.
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria at screening: Adult aged between 18 years and 74 years Focal epileptic seizures with or without secondary generalization Present treatment with one or two antiepileptic drugs (constant dosage during 8 weeks baseline phase prior to initiation of treatment with zonisamide). Stimulation of the vagus nerve is permitted and will not be counted as antiepileptic drug. For women of childbearing potential (postmenopausal for more than 1 year): possible pregnancy during the study can be excluded (by hysterectomy, sterilization or simultaneous application of two recognized methods of contraception (no oral contraceptives only) For male patients with partners of childbearing potential: a safe method of contraception is practiced during their study participation Written consent to participate in the study Inclusion criteria for randomisation: At least 6 focal or clonicotonic seizures documented completely in a seizure diary or the patient chart during the 8 prospective or retrospective weeks baseline phase. Exclusion criteria at screening: Epileptic state during the past year Non-epileptic fits Generalized epilepsy More than 4 weeks of seizure freedom during baseline phase Concomitant progressive CNS disease including progressive myoclonus epilepsy Concomitant treatment with vigabatrine and / or topiramate Hepatic and/or renal insufficiency (creatine > 2mg% or GPT > 2 times ULN) Body weight ≤ 40 kg (History of) kidney stones; erythrocyturia, family history (in parents, children, brothers and sisters or grandparents) of kidney stones (History of) drug and/or alcohol dependence Active psychosis Suicide attempt during the past 3 years Pre-treatment with zonisamide Known hypersensitivity to sulfonamides concomitant treatment with neuroleptic drugs pregnant or breast feeding woman participation in another therapy study within 3 months prior to or during this study blood donation planned during or within 4 weeks after the participation in this study elective surgery planned during the participation in this study patient is not willing or not capable to meet the study demands patient does not agree to the forwarding of his/her pseudonymous data patient without legal competence Exclusion criteria for randomisation: - More than 4 consecutive weeks of freedom from seizure during baseline phase
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christian Elger
Organizational Affiliation
Universitatsklinikum Bonn, Klinik fur Epileptologie
Official's Role
Principal Investigator
Facility Information:
Facility Name
Epilepsieklinik Tabor
City
Bernau
State/Province
Brandenburg
ZIP/Postal Code
16321
Country
Germany
Facility Name
Universtitatsklinikum Bonn
City
Bonn
State/Province
Nordrhein-Westphalen
ZIP/Postal Code
53105
Country
Germany
Facility Name
Universtitatsklinikum Munster, Klinik und Poliklinik fur Neurologie
City
Munster
State/Province
Nordrhein-Westphalen
ZIP/Postal Code
48129
Country
Germany
Facility Name
Epilepsiezentrum Bethel/KSE
City
Beilefeld
ZIP/Postal Code
33617
Country
Germany
Facility Name
Institut fur Diagnostik der Epilepsien Gmbh
City
Berlin
ZIP/Postal Code
10362
Country
Germany
Facility Name
Charite Campus Virchow-Klinikum, Neurologische Klinik und Poliklinik
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Facility Name
St. Josephs Hospital, Neurologische Klinik
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Facility Name
Dr. Gunther Schumann
City
Bochum
ZIP/Postal Code
44805
Country
Germany
Facility Name
Knappschaftskrankenhaus Bochum-Langendreer, Neurologische Klinik
City
Bochum
ZIP/Postal Code
44892
Country
Germany
Facility Name
Dr. Hans Martin Kolbinger
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
Neuro-Consil Gmbh
City
Dusseldorf
ZIP/Postal Code
40212
Country
Germany
Facility Name
Neurologische Klinik der Universitat Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Universitatsklinik Essen, Klinik und Poliklinik fur Neurologie
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Universitatsklinikum Freiburg, Neurozentrum
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Universitatsklinikum Gottingen, Abt. fur klinische Neurophysiologie
City
Gottingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Gemeinschaftpraxis fur Neurologie und Psychiatrie
City
Hamburg
ZIP/Postal Code
22083
Country
Germany
Facility Name
Dr. Heinrich C. Braeuer
City
Hamburg
ZIP/Postal Code
22299
Country
Germany
Facility Name
Ev. Krankenhaus Alsterdorf, Epilepsiezentrum Alsterdorf
City
Hamburg
ZIP/Postal Code
22337
Country
Germany
Facility Name
Epilepsiezentrum Kork
City
Kehl
ZIP/Postal Code
77694
Country
Germany
Facility Name
Epilepsiezentrum Kleinwachau, Epilepsieambulanz
City
Liegau-Augustusbad
ZIP/Postal Code
01465
Country
Germany
Facility Name
Universitatsklinikum Mannheim, Neurologische Klinik, Ambulanz fur Anfallserkrankte
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Universitatsklinikum, Interdisziplinares Epilepsiezentrum
City
Marburg
ZIP/Postal Code
35043
Country
Germany
Facility Name
Klinikum Grosshadern, Neurologische Klinik und Poliklinik, Epilepsie-Ambulanz
City
Munchen
ZIP/Postal Code
81377
Country
Germany
Facility Name
Klinikum Offenbach, Neurologie
City
Offenbach
ZIP/Postal Code
63069
Country
Germany
Facility Name
Klinik Ernst von Bergmann
City
Potsdam
ZIP/Postal Code
14467
Country
Germany
Facility Name
Universitat Regensburg, Klinik un Poliklinik fur Neurologie
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Klinik "Die Weissenau", Anfallsambulanz
City
Revensburg
ZIP/Postal Code
88214
Country
Germany
Facility Name
Universitat Rostock, Klinik fur Neurologie und Poliklinik
City
Rostock
ZIP/Postal Code
18147
Country
Germany
Facility Name
Universitatsklinik Ulm Poliklinik fur Neurologie, Epilepsieambulanz
City
Ulm
ZIP/Postal Code
89075
Country
Germany
Facility Name
Dr. Horst-Schmidt Klinik, Neurologie
City
Wiesbaden
ZIP/Postal Code
65199
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

We'll reach out to this number within 24 hrs